BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex Ventures HC...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS).Vertex Ventures HC...
...Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...with participation from SR One, Pfizer Ventures, Vertex Ventures HC...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Pharmaceuticals Inc. (NASDAQ:MACK), as well as a $32.5 million series A round led by Aisling. Vertex Ventures HC...
...Caris Life Sciences Inc. Number of employees: 5 Funds raised: $32.5 million Investors: Aisling Capital, Vertex Ventures HC...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...Funds raised: $82.8 million Investors: MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners, Premier Partners, Scripps Research and Vertex Ventures HC...
BioCentury | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

...of employees: About 40 Funds raised: $49.5 million Investors: Atlas Venture, GV, Takeda Ventures Inc., Vertex Ventures HC...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...partners: None Number of employees: 25 Funds raised: $47.6 million Investors: SR One, Pfizer Ventures, Vertex Ventures HC...
BioCentury | Sep 7, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
BioCentury | Sep 6, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
Items per page:
1 - 10 of 16
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex Ventures HC...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS).Vertex Ventures HC...
...Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures HC Sangamo...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...with participation from SR One, Pfizer Ventures, Vertex Ventures HC...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Pharmaceuticals Inc. (NASDAQ:MACK), as well as a $32.5 million series A round led by Aisling. Vertex Ventures HC...
...Caris Life Sciences Inc. Number of employees: 5 Funds raised: $32.5 million Investors: Aisling Capital, Vertex Ventures HC...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...Funds raised: $82.8 million Investors: MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
BioCentury | Jun 13, 2019
Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

...of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners, Premier Partners, Scripps Research and Vertex Ventures HC...
BioCentury | May 23, 2019
Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

...of employees: About 40 Funds raised: $49.5 million Investors: Atlas Venture, GV, Takeda Ventures Inc., Vertex Ventures HC...
BioCentury | Feb 8, 2019
Emerging Company Profile

Palleon: Sweeter checkpoints

...partners: None Number of employees: 25 Funds raised: $47.6 million Investors: SR One, Pfizer Ventures, Vertex Ventures HC...
BioCentury | Sep 7, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...A round co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
BioCentury | Sep 6, 2018
Financial News

Non-coding RNA company Twentyeight-Seven debuts with $65M

...series A co-led by MPM Capital and Novartis Venture Fund. Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures HC...
Items per page:
1 - 10 of 16